news
FDA Docket Shows Deep Industry Divide Over Psychedelic Therapy Rules
Public comments on the FDA's Part 15 hearing docket reveal fierce disagreement over how psychedelic medicines should be regulated. Drug developers are pushing for streamlined, pill-only approvals, while clinicians and trial monitors insist that pairing compounds with structured psychotherapy is mandatory for patient safety.
Public comments on the FDA's Part 15 hearing docket reveal fierce disagreement over how psychedelic medicines should be regulated. Drug developers are pushing for streamlined, pill-only approvals, while clinicians and trial monitors insist that pairing compounds with structured psychotherapy is mandatory for patient safety.
The architecture take
I read through the docket submissions, and the split isn't subtle. I used to assume FDA regulation for psilocybin and MDMA would stall out on basic toxicology, but the real brawl is over who sits in the room. Pharma sponsors want a neat pill: hit the 5-HT2A receptor, trigger acute neuroplasticity, and send someone home in four hours without funding two therapists at $150 an hour. Clinicians looking at trial data know that a flood of cortical connectivity can leave a person unmoored without guided integration. When you dissolve ego defenses, you also spike autonomic arousal; without trained co-regulation, patients end up with acute panic instead of relief. I changed my mind last year about whether pure biotech could decouple the molecule from the couch. It can't. Stripping out the human care makes the margin look better on paper, but it strips out the exact nervous system safety net that keeps an open state grounded.